NBIX
Price
$124.31
Change
-$0.70 (-0.56%)
Updated
Jun 13, 11:58 AM (EDT)
Capitalization
13.72B
53 days until earnings call
NTLA
Price
$8.30
Change
-$0.04 (-0.48%)
Updated
Jun 13, 04:59 PM (EDT)
Capitalization
864.92M
48 days until earnings call
TLRY
Price
$0.41
Change
-$0.01 (-2.38%)
Updated
Jun 13, 02:26 PM (EDT)
Capitalization
1.87B
40 days until earnings call
Interact to see
Advertisement

NBIX or NTLA or TLRY

Header iconNBIX vs NTLA vs TLRY Comparison
Open Charts NBIX vs NTLA vs TLRYBanner chart's image
Neurocrine Biosciences
Price$124.31
Change-$0.70 (-0.56%)
Volume$200
Capitalization13.72B
Intellia Therapeutics
Price$8.30
Change-$0.04 (-0.48%)
Volume$88.05K
Capitalization864.92M
Tilray Brands
Price$0.41
Change-$0.01 (-2.38%)
Volume$12.3K
Capitalization1.87B
NBIX vs NTLA vs TLRY Comparison Chart
Loading...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
Interact to see
Advertisement
COMPARISON
Comparison
Jun 13, 2025
Stock price -- (NBIX: $125.01NTLA: $8.35TLRY: $0.42)
Brand notoriety: NBIX and NTLA are not notable and TLRY is notable
NBIX and TLRY are part of the Pharmaceuticals: Other industry, and NTLA is in the Biotechnology industry
Current volume relative to the 65-day Moving Average: NBIX: 40%, NTLA: 58%, TLRY: 63%
Market capitalization -- NBIX: $13.72B, NTLA: $864.92M, TLRY: $1.87B
$NBIX [@Pharmaceuticals: Other] is valued at $13.72B. $TLRY’s [@Pharmaceuticals: Other] market capitalization is $ $1.87B. $NTLA [@Biotechnology] has a market capitalization of $ $864.92M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $ $77.48B to $ $0. The market cap for tickers in the [@Biotechnology] industry ranges from $ $352B to $ $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $ $3.78B. The average market capitalization across the [@Biotechnology] industry is $ $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBIX’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s), and TLRY’s FA Score reflects 0 green FA rating(s).

  • NBIX’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, NBIX is a better buy in the long-term than NTLA and TLRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBIX’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 7 bullish TA indicator(s), and TLRY’s TA Score reflects 5 bullish TA indicator(s).

  • NBIX’s TA Score: 3 bullish, 4 bearish.
  • NTLA’s TA Score: 7 bullish, 2 bearish.
  • TLRY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than TLRY, which in turn is a better option than NBIX.

Price Growth

NBIX (@Pharmaceuticals: Other) experienced а +0.32% price change this week, while NTLA (@Biotechnology) price change was +10.16% , and TLRY (@Pharmaceuticals: Other) price fluctuated +7.24% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.09%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +67.07%.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.16%. For the same industry, the average monthly price growth was +20.27%, and the average quarterly price growth was +6.37%.

Reported Earning Dates

NBIX is expected to report earnings on Aug 05, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.09% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Biotechnology (+8.16% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.7B) has a higher market cap than TLRY($1.87B) and NTLA($865M). NBIX YTD gains are higher at: -8.418 vs. NTLA (-28.388) and TLRY (-68.699). NBIX has higher annual earnings (EBITDA): 358M vs. NTLA (-530.8M) and TLRY (-1.23B). NBIX has more cash in the bank: 1.03B vs. NTLA (504M) and TLRY (260M). NTLA has less debt than NBIX and TLRY: NTLA (119M) vs NBIX (428M) and TLRY (529M). NBIX has higher revenues than TLRY and NTLA: NBIX (1.89B) vs TLRY (700M) and NTLA (45.6M).
NBIXNTLATLRY
Capitalization13.7B865M1.87B
EBITDA358M-530.8M-1.23B
Gain YTD-8.418-28.388-68.699
P/E Ratio57.20N/A8.52
Revenue1.89B45.6M700M
Total Cash1.03B504M260M
Total Debt428M119M529M
FUNDAMENTALS RATINGS
NBIX vs NTLA vs TLRY: Fundamental Ratings
NBIX
NTLA
TLRY
OUTLOOK RATING
1..100
2244
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
24
Undervalued
47
Fair valued
PROFIT vs RISK RATING
1..100
97100100
SMR RATING
1..100
609294
PRICE GROWTH RATING
1..100
528693
P/E GROWTH RATING
1..100
3410094
SEASONALITY SCORE
1..100
5075n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (24) in the Biotechnology industry is in the same range as TLRY (47) and is somewhat better than the same rating for NBIX (72). This means that NTLA's stock grew similarly to TLRY’s and somewhat faster than NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as NTLA (100) and is in the same range as TLRY (100). This means that NBIX's stock grew similarly to NTLA’s and similarly to TLRY’s over the last 12 months.

NBIX's SMR Rating (60) in the Biotechnology industry is in the same range as NTLA (92) and is somewhat better than the same rating for TLRY (94). This means that NBIX's stock grew similarly to NTLA’s and somewhat faster than TLRY’s over the last 12 months.

NBIX's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for NTLA (86) and is somewhat better than the same rating for TLRY (93). This means that NBIX's stock grew somewhat faster than NTLA’s and somewhat faster than TLRY’s over the last 12 months.

NBIX's P/E Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for TLRY (94) and is significantly better than the same rating for NTLA (100). This means that NBIX's stock grew somewhat faster than TLRY’s and significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBIXNTLATLRY
RSI
ODDS (%)
Bearish Trend 4 days ago
70%
N/A
Bullish Trend 5 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
56%
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 5 days ago
72%
Bullish Trend 4 days ago
77%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
62%
Bearish Trend 2 days ago
88%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSXIX41.22N/A
N/A
abrdn US Small Cap Equity Inst Svc
AASMX22.04N/A
N/A
Thrivent Small Cap Stock A
RSGFX11.13N/A
N/A
Victory RS Select Growth C
BSMIX16.56N/A
N/A
iShares Russell Small/Mid-Cap Idx Instl
TCIHX26.11N/A
N/A
Nuveen International Eq Idx I